These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 29315611

  • 1. Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.
    Gadermaier E, Marth K, Lupinek C, Campana R, Hofer G, Blatt K, Smiljkovic D, Roder U, Focke-Tejkl M, Vrtala S, Keller W, Valent P, Valenta R, Flicker S.
    Allergy; 2018 Jul; 73(7):1425-1435. PubMed ID: 29315611
    [Abstract] [Full Text] [Related]

  • 2. Characterization of the T-cell response to Dau c 1, the Bet v 1-homolog in carrot.
    Zulehner N, Nagl B, Briza P, Roulias A, Ballmer-Weber B, Zlabinger GJ, Ferreira F, Bohle B.
    Allergy; 2017 Feb; 72(2):244-251. PubMed ID: 27222434
    [Abstract] [Full Text] [Related]

  • 3. IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1.
    Grilo JR, Kitzmüller C, Aglas L, Sánchez Acosta G, Vollmann U, Ebner C, Horak F, Kinaciyan T, Radauer C, Ferreira F, Jahn-Schmid B, Bohle B.
    Allergy; 2021 Aug; 76(8):2555-2564. PubMed ID: 33724487
    [Abstract] [Full Text] [Related]

  • 4. Bet v 1-independent sensitization to major allergens in Fagales pollen: Evidence at the T-cell level.
    Polak D, Vollmann U, Grilo J, Bogdanov IV, Aglas L, Ovchinnikova TV, Ferreira F, Bohle B.
    Allergy; 2023 Mar; 78(3):743-751. PubMed ID: 36424884
    [Abstract] [Full Text] [Related]

  • 5. The role of IgG1 and IgG4 as dominant IgE-blocking antibodies shifts during allergen immunotherapy.
    Strobl MR, Demir H, Sánchez Acosta G, Drescher A, Kitzmüller C, Möbs C, Pfützner W, Bohle B.
    J Allergy Clin Immunol; 2023 May; 151(5):1371-1378.e5. PubMed ID: 36657603
    [Abstract] [Full Text] [Related]

  • 6. Construction of a Hybrid Vaccine Based on Der f 35-Derived Peptides with Reduced Allergenicity.
    Hu H, Qin QZ, Zheng W, Xu ZQ, Chen X.
    Int Arch Allergy Immunol; 2024 Nov 26; ():1-17. PubMed ID: 39591953
    [Abstract] [Full Text] [Related]

  • 7. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM, Thom H, Sheppard AL, Keeney E, O'Donnell R, Jackson J, Roadevin C, Dawson S, Lane D, Stubbs J, Everitt H, Watson JC, Hay AD, Gillett P, Robins G, Jones HE, Mallett S, Whiting PF.
    Health Technol Assess; 2022 Oct 26; 26(44):1-310. PubMed ID: 36321689
    [Abstract] [Full Text] [Related]

  • 8. Unique allergen-specific human IgE monoclonal antibodies derived from patients with allergic disease.
    Smith BRE, Reid Black K, Bermingham M, Agah S, Glesner J, Versteeg SA, van Ree R, Pena-Amelunxen G, Aglas L, Smith SA, Pomés A, Chapman MD.
    Front Allergy; 2023 Oct 26; 4():1270326. PubMed ID: 37901762
    [Abstract] [Full Text] [Related]

  • 9. Easy assessment of the avidity of polyclonal allergen-specific serum antibodies.
    Strobl MR, Demir H, Wozniak-Knopp G, Wangorsch A, Rüker F, Bohle B.
    Clin Exp Allergy; 2024 Apr 26; 54(4):278-285. PubMed ID: 38183336
    [Abstract] [Full Text] [Related]

  • 10. Bet v 1-displaying elastin-like polypeptide nanoparticles induce a strong humoral and weak CD4+ T-cell response against Bet v 1 in a murine immunogenicity model.
    van Strien J, Warmenhoven H, Logiantara A, Makurat M, Aglas L, Bethanis A, Leboux R, van Rijt L, MacKay JA, van Schijndel JW, Schneider G, Olsthoorn R, Jiskoot W, van Ree R, Kros A.
    Front Immunol; 2022 Apr 26; 13():1006776. PubMed ID: 36275650
    [Abstract] [Full Text] [Related]

  • 11. A Novel Quality Control Strategy for the Preparation of High-Quality Recombinant Allergens in Escherichia coli: A Case Study of Der f 2.
    Tang J, Yang DZ, Lu C, Zheng W, Hu ZM, Xu YF, Li K, Wei JF, Xu ZQ.
    Int Arch Allergy Immunol; 2024 Apr 26; 185(12):1166-1178. PubMed ID: 39047720
    [Abstract] [Full Text] [Related]

  • 12. Antioxidants for female subfertility.
    Showell MG, Mackenzie-Proctor R, Jordan V, Hart RJ.
    Cochrane Database Syst Rev; 2020 Aug 27; 8(8):CD007807. PubMed ID: 32851663
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH.
    Clin Orthop Relat Res; 2024 Dec 01; 482(12):2193-2208. PubMed ID: 39051924
    [Abstract] [Full Text] [Related]

  • 14.
    Kirtsoglou E, Simpson B, Salisbury L, Baraitser L.
    ; 2020 Dec 01. PubMed ID: 36137063
    [Abstract] [Full Text] [Related]

  • 15. Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results.
    Wing K, Williamson E, Carpenter JR, Wise L, Schneeweiss S, Smeeth L, Quint JK, Douglas I.
    Health Technol Assess; 2021 Aug 01; 25(51):1-70. PubMed ID: 34463610
    [Abstract] [Full Text] [Related]

  • 16. Lung mucosal immunity to NTHi vaccine antigens: Antibodies in sputum of chronic obstructive pulmonary disease patients.
    Baffetta F, Buonsanti C, Moraschini L, Aprea S, Canè M, Lombardi S, Contorni M, Rondini S, Arora AK, Bardelli M, Finco O, Serruto D, Paccani SR.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2343544. PubMed ID: 38655676
    [Abstract] [Full Text] [Related]

  • 17. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S, Kearns B, Scope A, Schmitt L, Jankovic D, Hamilton J, Srivastava T, Hill H, Ku CC, Ren S, Rothery C, Bojke L, Sculpher M, Woods B.
    Health Technol Assess; 2024 Oct 31; 28(73):1-230. PubMed ID: 39487661
    [Abstract] [Full Text] [Related]

  • 18. Cosensitization to the 3 Nonhomologous Major Cashew Allergens Ana o 1, Ana o 2, and Ana o 3 Is Caused by IgE Cross-reactivity.
    Kabasser S, Radauer C, Eber E, Haber ME, Hieden K, Zieglmayer P, Kost LE, Sindher SB, Chinthrajah S, Geiselhart S, Hoffmann-Sommergruber K, Nadeau KC, Breiteneder H, Bublin M.
    J Investig Allergol Clin Immunol; 2024 Feb 22; 34(1):38-48. PubMed ID: 36331131
    [Abstract] [Full Text] [Related]

  • 19. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J, Gaudet LA, Saba S, Vandermeer B, Ashiq AR, Wingert A, Hartling L.
    Syst Rev; 2024 Nov 26; 13(1):289. PubMed ID: 39593159
    [Abstract] [Full Text] [Related]

  • 20. Reducing the solubility of the major birch pollen allergen Bet v 1 by particle-loading mitigates Th2 responses.
    Kraiem A, Pelamatti E, Grosse-Kathoefer S, Demir H, Vollmann U, Ehgartner C, Stigler M, Punz B, Johnson L, Hüsing N, Bohle B, Aglas L.
    Allergol Int; 2024 Aug 17. PubMed ID: 39155214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.